In many breast cancers, ER (alpha) activation by estrogens is generally considered responsible for enhanced proliferation, whereas that is counteracted by the presence of ER (beta),which exerts an antiproliferative effect. Please devise a strategy targeting both receptors for the treatment of this disease.

Biology 2e
2nd Edition
ISBN:9781947172517
Author:Matthew Douglas, Jung Choi, Mary Ann Clark
Publisher:Matthew Douglas, Jung Choi, Mary Ann Clark
Chapter17: Biotechnology And Genomics
Section: Chapter Questions
Problem 3VCQ: Figure 17.15 In 2011, the United States Preventative Services Task Force recommended against using...
icon
Related questions
icon
Concept explainers
Question
100%

In many breast cancers, ER (alpha) activation by estrogens is generally considered responsible for enhanced proliferation, whereas that is counteracted by the presence of ER (beta),which exerts an antiproliferative effect. Please devise a strategy targeting both receptors for the treatment of this disease.

•This question relates to the selectivity of different drugs for the treatment of Ovarian Cancer.
The expression of the two Estrogen Receptors subtypes, ERa and ERß, was investigated in two
human ovarian cancer cell lines, A and B, using Western Blotting of the whole cell fraction (Figure 1).
The inhibitory effect on the cellular growth of the natural hormone estradiol (E2) and two different drugs (KB9520 and PPT) was studied
for both cell lines using a Trypan Blue assay. Figure 2 shows a plot of the inhibition of cell proliferation versus control of the compounds
E2, KB9520 and PPT at increasing concentrations. A full agonist is expected to exert 100% inhibition of the cell proliferation for both cell
lines
A B
ERa
ERB
Tubulin
Figure 1 - Western Blot
% inhibition versus control
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
Cell line A
с 0,1 nM
1 nM 5 nM 10 nM
KB9520 E2 OPPT
% inhibition versus control
60
50
40
30
20
10
0
-10
C
Cell line B
0,1 nM
1 nM
■KB9520
10 nM
5 nM
E2 OPPT
Figure 2 - Inhibition of cell proliferation for cell lines A and B under treatment with KB9520, E2 or PPT
Transcribed Image Text:•This question relates to the selectivity of different drugs for the treatment of Ovarian Cancer. The expression of the two Estrogen Receptors subtypes, ERa and ERß, was investigated in two human ovarian cancer cell lines, A and B, using Western Blotting of the whole cell fraction (Figure 1). The inhibitory effect on the cellular growth of the natural hormone estradiol (E2) and two different drugs (KB9520 and PPT) was studied for both cell lines using a Trypan Blue assay. Figure 2 shows a plot of the inhibition of cell proliferation versus control of the compounds E2, KB9520 and PPT at increasing concentrations. A full agonist is expected to exert 100% inhibition of the cell proliferation for both cell lines A B ERa ERB Tubulin Figure 1 - Western Blot % inhibition versus control 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 Cell line A с 0,1 nM 1 nM 5 nM 10 nM KB9520 E2 OPPT % inhibition versus control 60 50 40 30 20 10 0 -10 C Cell line B 0,1 nM 1 nM ■KB9520 10 nM 5 nM E2 OPPT Figure 2 - Inhibition of cell proliferation for cell lines A and B under treatment with KB9520, E2 or PPT
Expert Solution
steps

Step by step

Solved in 4 steps

Blurred answer
Knowledge Booster
Cancer therapy
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Biology 2e
Biology 2e
Biology
ISBN:
9781947172517
Author:
Matthew Douglas, Jung Choi, Mary Ann Clark
Publisher:
OpenStax